Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2016 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Other Non-Current Assets of $1.7 million for Q1 2026, up 173.45% year-over-year from $629000.0 in Q1 2025, and up 101.17% quarter-over-quarter from $855000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 173.45% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 173.45% YoY), while the FY2025 annual figure was $855000.0, up 35.28% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.7 million, up from $855000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.7 million in Q1 2026, with the low at $89000.0 in Q3 2023.
- The 5-year median for Other Non-Current Assets is $236000.0 (2022), against an average of $415823.5.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets tumbled 78.11% in 2022, then surged 610.11% in 2024.
- Corvus Pharmaceuticals' Other Non-Current Assets stood at $129000.0 in 2022, then tumbled by 31.01% to $89000.0 in 2023, then soared by 610.11% to $632000.0 in 2024, then jumped by 35.28% to $855000.0 in 2025, then jumped by 101.17% to $1.7 million in 2026.
- Business Quant data shows CRVS's Other Non-Current Assets at $1.7 million in Q1 2026, $855000.0 in Q4 2025, and $852000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 855,000.00 |
| Sep 30, 2025 | 852,000.00 |
| Jun 30, 2025 | 626,000.00 |
| Mar 31, 2025 | 629,000.00 |
| Dec 31, 2024 | 632,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 89,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Mar 31, 2023 | 129,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Sep 30, 2022 | 248,000.00 |
| Jun 30, 2022 | 236,000.00 |
| Mar 31, 2022 | 236,000.00 |
| Dec 31, 2021 | 236,000.00 |
| Sep 30, 2021 | 279,000.00 |